国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2010年
2期
110-113
,共4页
促红细胞生成素%受体,促红细胞生成素%肿瘤
促紅細胞生成素%受體,促紅細胞生成素%腫瘤
촉홍세포생성소%수체,촉홍세포생성소%종류
Erythropoietin%Receptors,Erythropoietin%Neoplasms
研究发现,促红细胞生成素(EPO)及EPO受体(EPOR)在多种恶性肿瘤组织中表达,且EPO能促进肿瘤微血管形成,刺激肿瘤细胞增殖,抑制凋亡,还调节肿瘤细胞对放化疔治疗的敏感性.另有研究表明,EPO的应用不利于肿瘤的控制和预后.EPO对肿瘤患者的疾病进展和生存期的影响仍需进一步研究.
研究髮現,促紅細胞生成素(EPO)及EPO受體(EPOR)在多種噁性腫瘤組織中錶達,且EPO能促進腫瘤微血管形成,刺激腫瘤細胞增殖,抑製凋亡,還調節腫瘤細胞對放化疔治療的敏感性.另有研究錶明,EPO的應用不利于腫瘤的控製和預後.EPO對腫瘤患者的疾病進展和生存期的影響仍需進一步研究.
연구발현,촉홍세포생성소(EPO)급EPO수체(EPOR)재다충악성종류조직중표체,차EPO능촉진종류미혈관형성,자격종류세포증식,억제조망,환조절종류세포대방화정치료적민감성.령유연구표명,EPO적응용불리우종류적공제화예후.EPO대종류환자적질병진전화생존기적영향잉수진일보연구.
Recent studies have shown that erythropoietin (EPO) and its specific receptor (EPOR) are expressed in malignant tumors, and EPO was found to promote tumor angiogenesis and proliferation, inhibit tumor cell apoptosis,or regulate sensitivity to chemoradiothrapy. moreover,several clinical researches have also shown that EPO was not associated with improved cancer control or survival. Further,preclinical experiments will have to elucidate the multiple molecular effects of EPO on tumor progression and survival in cancer patients.
